Trial Profile
Edaravone-sodium ozagrel (thromboxane A2 synthase inhibitor) comparative post-marketing study on acute ischemic stroke
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Edaravone (Primary) ; Ozagrel
- Indications Embolism and thrombosis; Stroke
- Focus Therapeutic Use
- Acronyms EDO
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 10 Nov 2009 Actual number of patients (401) added as reported by ClinicalTrials.gov.
- 27 Dec 2007 Status changed from in progress to completed.
- 28 Aug 2006 Status change